首页 > 最新文献

Journal of Clinical Microbiology最新文献

英文 中文
Reverse-transcriptase real-time PCR in the diagnostic strategy for invasive infections caused by Aspergillus fumigatus. 反转录酶实时荧光定量PCR技术在曲霉菌侵袭性感染诊断策略中的应用。
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-24 DOI: 10.1128/jcm.00791-24
Charles Gibert, Pauline Tirard-Collet, Charline Miossec, Damien Dupont, Florence Persat, Martine Wallon, Florence Ader, Gilles Devouassoux, Sophie Ducastelle, Hélène Labussière-Wallet, Sylvie Paulus, Céline Guichon, Anne-Claire Lukaszewicz, Jean-Christophe Richard, Florent Wallet, Alexandre Alanio, Meja Rabodonirina, Jean Menotti

The aim was to develop an RT-qPCR targeting Aspergillus fumigatus and compare its performance to that of Aspergillus fumigatus qPCR for the diagnosis of invasive aspergillosis (IA). Samples from patients of the Lyon University hospitals for whom a suspicion of IA led to the realization of an Aspergillus fumigatus qPCR molecular diagnostic test over a 2-year period were included. The patients were classified according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC-MSGERC) criteria for suspected IA; RT-qPCR and qPCR assays were performed on all included samples. The sensitivities and specificities of RT-qPCR and qPCR were calculated and compared using the results of the EORTC-MSGERC classification as reference. The cycle threshold (Ct) results were compared according to IA classification and sample type. Among the 193 samples analyzed, 91 were classified as IA excluded, 46 as possible IA, 53 as probable IA, and 3 as proven IA. For all sample types, RT-qPCR was significantly more sensitive than qPCR for all IA classifications with an additional 17/102 samples detected (P-value < 0.01). For plasma samples, sensitivity was significantly higher and specificity significantly lower using RT-qPCR for all IA classifications (P-value < 0.001). The mean Ct obtained with RT-qPCR were significantly lower than those obtained with qPCR for all IA classifications and all sample types (P-value < 0.001 and P-value < 0.0001, respectively). RT-qPCR presents a higher sensitivity than qPCR for the diagnosis of IA due to Aspergillus fumigatus, particularly in samples with an intrinsically low fungal load.IMPORTANCEAspergillus fumigatus belongs to the critical priority group of the World Health Organization fungal priority pathogens list. Invasive aspergillosis (IA) is a life-threatening infection with poor prognosis and challenging diagnosis. PCR has been integrated into the 2020 European Organization for Research and Treatment of Cancer/Mycoses Study Group consensus definitions for IA diagnosis. However, due to frequent low fungal burdens, its sensitivity needs to be improved. This work presents an innovative method for detecting total nucleic acids, corresponding to both ribosomal RNA and DNA, that enables IA diagnosis with greater sensitivity than conventional techniques, especially in non-invasive samples such as blood, enhancing the monitoring of this infection in high-risk patients.

我们的目的是开发一种针对曲霉菌的 RT-qPCR,并比较其与烟曲霉菌 qPCR 在诊断侵袭性曲霉菌病(IA)方面的性能。里昂大学医院在两年内对怀疑患有侵袭性曲霉菌病的患者进行了曲霉菌 qPCR 分子诊断检测。根据欧洲癌症研究和治疗组织/霉菌病研究小组(EORTC-MSGERC)的疑似 IA 标准对患者进行了分类;对所有纳入的样本进行了 RT-qPCR 和 qPCR 检测。以 EORTC-MSGERC 分类结果为参考,计算并比较了 RT-qPCR 和 qPCR 的敏感性和特异性。根据 IA 分类和样本类型对周期阈值(Ct)结果进行了比较。在分析的 193 份样本中,91 份被归类为排除 IA,46 份被归类为可能 IA,53 份被归类为可能 IA,3 份被归类为已证实 IA。在所有样本类型中,RT-qPCR 对所有 IA 分类的灵敏度明显高于 qPCR,多检测出 17/102 个样本(P 值 < 0.01)。对于血浆样本,使用 RT-qPCR 检测所有 IA 分类的灵敏度明显更高,特异性明显更低(P 值 < 0.001)。就所有 IA 分类和所有样本类型而言,使用 RT-qPCR 获得的平均 Ct 值明显低于使用 qPCR 获得的平均 Ct 值(P 值分别 < 0.001 和 P 值 < 0.0001)。在诊断由烟曲霉引起的侵袭性曲霉病时,RT-qPCR 比 qPCR 具有更高的灵敏度,尤其是在真菌含量固有较低的样本中。重要意义烟曲霉属于世界卫生组织真菌优先病原体名单中的关键优先组。侵袭性曲霉菌病(IA)是一种危及生命的感染,预后不良,诊断困难。PCR 已被纳入 2020 年欧洲癌症研究和治疗组织/真菌病研究小组关于 IA 诊断的共识定义。然而,由于真菌负担经常较低,其灵敏度有待提高。本研究提出了一种检测核糖体RNA和DNA总核酸的创新方法,与传统技术相比,该方法可提高IA诊断的灵敏度,尤其是在血液等非侵入性样本中,从而加强对高危患者感染情况的监测。
{"title":"Reverse-transcriptase real-time PCR in the diagnostic strategy for invasive infections caused by <i>Aspergillus fumigatus</i>.","authors":"Charles Gibert, Pauline Tirard-Collet, Charline Miossec, Damien Dupont, Florence Persat, Martine Wallon, Florence Ader, Gilles Devouassoux, Sophie Ducastelle, Hélène Labussière-Wallet, Sylvie Paulus, Céline Guichon, Anne-Claire Lukaszewicz, Jean-Christophe Richard, Florent Wallet, Alexandre Alanio, Meja Rabodonirina, Jean Menotti","doi":"10.1128/jcm.00791-24","DOIUrl":"https://doi.org/10.1128/jcm.00791-24","url":null,"abstract":"<p><p>The aim was to develop an RT-qPCR targeting <i>Aspergillus fumigatus</i> and compare its performance to that of <i>Aspergillus fumigatus</i> qPCR for the diagnosis of invasive aspergillosis (IA). Samples from patients of the Lyon University hospitals for whom a suspicion of IA led to the realization of an <i>Aspergillus fumigatus</i> qPCR molecular diagnostic test over a 2-year period were included. The patients were classified according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC-MSGERC) criteria for suspected IA; RT-qPCR and qPCR assays were performed on all included samples. The sensitivities and specificities of RT-qPCR and qPCR were calculated and compared using the results of the EORTC-MSGERC classification as reference. The cycle threshold (Ct) results were compared according to IA classification and sample type. Among the 193 samples analyzed, 91 were classified as IA excluded, 46 as possible IA, 53 as probable IA, and 3 as proven IA. For all sample types, RT-qPCR was significantly more sensitive than qPCR for all IA classifications with an additional 17/102 samples detected (<i>P</i>-value < 0.01). For plasma samples, sensitivity was significantly higher and specificity significantly lower using RT-qPCR for all IA classifications (<i>P</i>-value < 0.001). The mean Ct obtained with RT-qPCR were significantly lower than those obtained with qPCR for all IA classifications and all sample types (<i>P</i>-value < 0.001 and <i>P</i>-value < 0.0001, respectively). RT-qPCR presents a higher sensitivity than qPCR for the diagnosis of IA due to <i>Aspergillus fumigatus</i>, particularly in samples with an intrinsically low fungal load.IMPORTANCE<i>Aspergillus fumigatus</i> belongs to the critical priority group of the World Health Organization fungal priority pathogens list. Invasive aspergillosis (IA) is a life-threatening infection with poor prognosis and challenging diagnosis. PCR has been integrated into the 2020 European Organization for Research and Treatment of Cancer/Mycoses Study Group consensus definitions for IA diagnosis. However, due to frequent low fungal burdens, its sensitivity needs to be improved. This work presents an innovative method for detecting total nucleic acids, corresponding to both ribosomal RNA and DNA, that enables IA diagnosis with greater sensitivity than conventional techniques, especially in non-invasive samples such as blood, enhancing the monitoring of this infection in high-risk patients.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Host blood protein biomarkers to screen for tuberculosis disease: a systematic review and meta-analysis. 用于筛查结核病的宿主血液蛋白生物标志物:系统综述和荟萃分析。
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-24 DOI: 10.1128/jcm.00786-24
Mary Gaeddert, Kerstin Glaser, Bih H Chendi, Ayten Sultanli, Lisa Koeppel, Emily L MacLean, Tobias Broger, Claudia M Denkinger

Non-sputum tests are needed to improve tuberculosis (TB) diagnosis and close the diagnostic gap. The World Health Organization's target product profile (TPP) for point-of-care (POC) screening tests requires a minimum sensitivity of 90% and a specificity of 70%. Our objective was to identify host blood protein biomarkers meeting TPP criteria. A systematic review was conducted and reported following PRISMA guidelines. Data extraction and quality assessment with Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) were completed for the included studies. Heterogeneity was assessed. For biomarkers reporting sensitivity and specificity in at least four studies, a random-effects meta-analysis was performed for biomarkers with similar cut-offs. We screened 4,651 citations and included 65 studies that enrolled 16,010 participants and evaluated 156 host proteins. Most (47/65) studies enrolled adult pulmonary TB (PTB), with 15 studies in adult extra-pulmonary TB and 5 in children. Small early-stage discovery studies with case-control design were common (24/65) and had a high risk of bias. For adult PTB, CRP, IP-10, NCAM-1, and SAA met TPP criteria in high-quality studies. There was a high degree of heterogeneity in biomarker cut-offs and study design. CRP at 10 mg/L cut-off was meta-analyzed from 10 studies; pooled sensitivity 86% [95% confidence interval (CI): 80-95] and pooled specificity 67% (95% CI: 54-79). In people living with HIV (six studies), CRP pooled sensitivity was 93% (95% CI: 90-95), and pooled specificity was 59% (95% CI: 40-78). We identified promising biomarkers that performed well in high-quality studies. Data overall are limited and highly heterogenous. Further standardized validation across subgroups in prospective studies is needed before translating into POC assays.

Importance: To our knowledge, this is the first comprehensive systematic review of host blood protein biomarkers for tuberculosis (TB), and we identified promising biomarkers for a TB screening test.

要改善结核病(TB)诊断并缩小诊断差距,就需要非痰检验。世界卫生组织针对床旁(POC)筛查检验的目标产品规格(TPP)要求灵敏度至少达到 90%,特异性至少达到 70%。我们的目标是找出符合 TPP 标准的宿主血液蛋白生物标志物。我们按照 PRISMA 指南进行了系统综述和报告。对纳入的研究进行了数据提取和诊断准确性研究质量评估-2(QUADAS-2)质量评估。对异质性进行了评估。对于至少有四项研究报告了敏感性和特异性的生物标志物,我们对具有相似临界值的生物标志物进行了随机效应荟萃分析。我们筛选了 4,651 篇引文,纳入了 65 项研究,这些研究共招募了 16,010 名参与者,评估了 156 种宿主蛋白质。大多数研究(47/65)的研究对象是成人肺结核(PTB),15 项研究的对象是成人肺外结核,5 项研究的对象是儿童。采用病例对照设计的小型早期发现研究很常见(24/65),偏倚风险很高。对于成人 PTB,CRP、IP-10、NCAM-1 和 SAA 符合高质量研究的 TPP 标准。生物标志物的临界值和研究设计存在高度异质性。10 项研究对 CRP 的 10 mg/L 临界值进行了荟萃分析;汇总灵敏度为 86%[95% 置信区间 (CI):80-95],汇总特异性为 67%(95% CI:54-79)。在艾滋病毒感染者中(6 项研究),CRP 的集合灵敏度为 93%(95% CI:90-95),集合特异性为 59%(95% CI:40-78)。我们发现了在高质量研究中表现良好的有前景的生物标志物。总体数据有限且高度异质性。在转化为 POC 检测方法之前,还需要在前瞻性研究中对不同亚组进行进一步的标准化验证:据我们所知,这是对结核病(TB)宿主血液蛋白生物标志物的首次全面系统综述,我们为结核病筛查检验确定了有前景的生物标志物。
{"title":"Host blood protein biomarkers to screen for tuberculosis disease: a systematic review and meta-analysis.","authors":"Mary Gaeddert, Kerstin Glaser, Bih H Chendi, Ayten Sultanli, Lisa Koeppel, Emily L MacLean, Tobias Broger, Claudia M Denkinger","doi":"10.1128/jcm.00786-24","DOIUrl":"https://doi.org/10.1128/jcm.00786-24","url":null,"abstract":"<p><p>Non-sputum tests are needed to improve tuberculosis (TB) diagnosis and close the diagnostic gap. The World Health Organization's target product profile (TPP) for point-of-care (POC) screening tests requires a minimum sensitivity of 90% and a specificity of 70%. Our objective was to identify host blood protein biomarkers meeting TPP criteria. A systematic review was conducted and reported following PRISMA guidelines. Data extraction and quality assessment with Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) were completed for the included studies. Heterogeneity was assessed. For biomarkers reporting sensitivity and specificity in at least four studies, a random-effects meta-analysis was performed for biomarkers with similar cut-offs. We screened 4,651 citations and included 65 studies that enrolled 16,010 participants and evaluated 156 host proteins. Most (47/65) studies enrolled adult pulmonary TB (PTB), with 15 studies in adult extra-pulmonary TB and 5 in children. Small early-stage discovery studies with case-control design were common (24/65) and had a high risk of bias. For adult PTB, CRP, IP-10, NCAM-1, and SAA met TPP criteria in high-quality studies. There was a high degree of heterogeneity in biomarker cut-offs and study design. CRP at 10 mg/L cut-off was meta-analyzed from 10 studies; pooled sensitivity 86% [95% confidence interval (CI): 80-95] and pooled specificity 67% (95% CI: 54-79). In people living with HIV (six studies), CRP pooled sensitivity was 93% (95% CI: 90-95), and pooled specificity was 59% (95% CI: 40-78). We identified promising biomarkers that performed well in high-quality studies. Data overall are limited and highly heterogenous. Further standardized validation across subgroups in prospective studies is needed before translating into POC assays.</p><p><strong>Importance: </strong>To our knowledge, this is the first comprehensive systematic review of host blood protein biomarkers for tuberculosis (TB), and we identified promising biomarkers for a TB screening test.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An update on novel taxa and revised taxonomic status of bacteria isolated from aquatic host species described in 2022-2023. 关于 2022-2023 年描述的从水生宿主物种中分离的细菌的新分类群和修订分类地位的最新情况。
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-24 DOI: 10.1128/jcm.01043-24
Claire R Burbick, Sara D Lawhon, Brittany Bukouras, Giovanna Lazzerini, Erik Munson

The description of new taxa and nomenclature updates to currently known taxa from aquatic animal species continues. After a review of the literature from 2022 and 2023, multiple lists of bacteria, including members of Phylum Planctomycetota, were compiled. As with the previous review, most bacteria are oxidase-positive Gram-negative bacilli with familiar families including new taxa in Aeromonadaceae, Flavobacteriaceae, and Vibrionaceae. A number of Gram-positive bacilli are described including new taxa in the Nocardioides, Paenibacillus, and Streptomyces genera. Two anaerobic species are listed, and one new member of Family Planctomycetaceae is noted. Revised taxa are briefly mentioned. The majority of new and revised taxa are isolated from healthy aquatic animals, and therefore, the role of these new bacteria in health and disease is unknown. Bacteria with pathogenic association and potential production of bioactive substances are highlighted.

新类群的描述和目前已知水生动物类群的命名更新工作仍在继续。在对 2022 年和 2023 年的文献进行回顾后,编制了多个细菌列表,其中包括 Planctomycetota 门的成员。与之前的回顾一样,大多数细菌都是氧化酶阳性革兰氏阴性杆菌,其中包括熟悉的科,包括气单胞菌科(Aeromonadaceae)、黄杆菌科(Flavobacteriaceae)和弧菌科(Vibrionaceae)中的新类群。描述了一些革兰氏阳性杆菌,包括 Nocardioides 属、Paenibacillus 属和 Streptomyces 属中的新类群。还列出了两个厌氧菌种,并指出了 Planctomycetaceae 科的一个新成员。简要提及了修订类群。大多数新分类群和修订分类群都是从健康水生动物中分离出来的,因此这些新细菌在健康和疾病中的作用尚不清楚。重点介绍了具有致病性和可能产生生物活性物质的细菌。
{"title":"An update on novel taxa and revised taxonomic status of bacteria isolated from aquatic host species described in 2022-2023.","authors":"Claire R Burbick, Sara D Lawhon, Brittany Bukouras, Giovanna Lazzerini, Erik Munson","doi":"10.1128/jcm.01043-24","DOIUrl":"https://doi.org/10.1128/jcm.01043-24","url":null,"abstract":"<p><p>The description of new taxa and nomenclature updates to currently known taxa from aquatic animal species continues. After a review of the literature from 2022 and 2023, multiple lists of bacteria, including members of Phylum <i>Planctomycetota</i>, were compiled. As with the previous review, most bacteria are oxidase-positive Gram-negative bacilli with familiar families including new taxa in <i>Aeromonadaceae</i>, <i>Flavobacteriaceae</i>, <i>and Vibrionaceae</i>. A number of Gram-positive bacilli are described including new taxa in the <i>Nocardioides</i>, <i>Paenibacillus</i>, and <i>Streptomyces</i> genera. Two anaerobic species are listed, and one new member of Family <i>Planctomycetaceae</i> is noted. Revised taxa are briefly mentioned. The majority of new and revised taxa are isolated from healthy aquatic animals, and therefore, the role of these new bacteria in health and disease is unknown. Bacteria with pathogenic association and potential production of bioactive substances are highlighted.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel machine-learning aided platform for rapid detection of urine ESBLs and carbapenemases: URECA-LAMP. 用于快速检测尿液中 ESBLs 和碳青霉烯酶的新型机器学习辅助平台:URECA-LAMP。
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-24 DOI: 10.1128/jcm.00869-24
L Ricardo Castellanos, Ryan Chaffee, Hitendra Kumar, Biniyam Kahsay Mezgebo, Pawulos Kassau, Gisele Peirano, Johann D D Pitout, Keekyoung Kim, Dylan R Pillai

Pathogenic gram-negative bacteria frequently carry genes encoding extended-spectrum beta-lactamases (ESBL) and/or carbapenemases. Of great concern are carbapenem resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Despite the need for rapid AMR diagnostics globally, current molecular detection methods often require expensive equipment and trained personnel. Here, we present a novel machine-learning-aided platform for the rapid detection of ESBLs and carbapenemases using Loop-mediated isothermal Amplification (LAMP). The platform consists of (i) an affordable device for sample lysis, LAMP amplification, and visual fluorometric detection; (ii) a LAMP screening panel to detect the most common ESBL and carbapenemase genes; and (iii) a smartphone application for automated interpretation of results. Validation studies on clinical isolates and urine samples demonstrated percent positive and negative agreements above 95% for all targets. Accuracy, precision, and recall values of the machine learning model deployed in the smartphone application were all above 92%. Providing a simplified workflow, minimal operation training, and results in less than an hour, this study demonstrated the platform's feasibility for near-patient testing in resource-limited settings.IMPORTANCEExtended-spectrum beta-lactamases (ESBL) and carbapenemases confer resistance to third-generation cephalosporins and carbapenems in pathogenic Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Conventional antimicrobial susceptibility testing is based on phenotypic methods, and results can take several days to be obtained. Current genotypic detection methods can be rapid but require expensive equipment and trained personnel. In this study, we present a novel machine learning-aided platform for the rapid detection of ESBLs and carbapenemases using Loop-mediated isothermal Amplification (LAMP). The validation of the platform demonstrated percent positive and negative agreements above 95% for all targets. The newly developed platform provided a simplified workflow, minimal technical training, and results in less than an hour. This study demonstrated the platform's feasibility for rapid testing of ESBL and carbapenemases in bacteria and urine specimens.

致病性革兰氏阴性菌经常携带编码广谱β-内酰胺酶(ESBL)和/或碳青霉烯酶的基因。耐碳青霉烯类的大肠埃希菌、肺炎克雷伯氏菌、铜绿假单胞菌和鲍曼不动杆菌最令人担忧。尽管全球都需要快速的 AMR 诊断,但目前的分子检测方法往往需要昂贵的设备和训练有素的人员。在此,我们介绍一种新型机器学习辅助平台,利用环路介导等温扩增(LAMP)技术快速检测 ESBLs 和碳青霉烯酶。该平台包括:(i) 用于样品裂解、LAMP 扩增和可视荧光检测的经济型设备;(ii) 用于检测最常见 ESBL 和碳青霉烯酶基因的 LAMP 筛选面板;(iii) 用于自动解读结果的智能手机应用程序。对临床分离物和尿液样本进行的验证研究表明,所有目标的阳性和阴性一致率均超过 95%。智能手机应用中部署的机器学习模型的准确度、精确度和召回值均超过 92%。这项研究提供了简化的工作流程、最少的操作培训和不到一小时的结果,证明了该平台在资源有限的环境中进行就近病人检测的可行性。重要意义扩展谱β-内酰胺酶(ESBL)和碳青霉烯酶使大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌和鲍曼不动杆菌等致病性革兰氏阴性菌对第三代头孢菌素和碳青霉烯类产生耐药性。传统的抗菌药敏感性检测以表型法为基础,需要几天时间才能得出结果。目前的基因型检测方法虽然快速,但需要昂贵的设备和训练有素的人员。在本研究中,我们提出了一种新型机器学习辅助平台,利用环路介导等温扩增法(LAMP)快速检测 ESBLs 和碳青霉烯酶。该平台的验证结果表明,所有目标的阳性和阴性一致率均超过 95%。新开发的平台简化了工作流程,只需极少的技术培训,不到一小时就能得出结果。这项研究证明了该平台在快速检测细菌和尿液标本中的 ESBL 和碳青霉烯酶方面的可行性。
{"title":"A novel machine-learning aided platform for rapid detection of urine ESBLs and carbapenemases: URECA-LAMP.","authors":"L Ricardo Castellanos, Ryan Chaffee, Hitendra Kumar, Biniyam Kahsay Mezgebo, Pawulos Kassau, Gisele Peirano, Johann D D Pitout, Keekyoung Kim, Dylan R Pillai","doi":"10.1128/jcm.00869-24","DOIUrl":"https://doi.org/10.1128/jcm.00869-24","url":null,"abstract":"<p><p>Pathogenic gram-negative bacteria frequently carry genes encoding extended-spectrum beta-lactamases (ESBL) and/or carbapenemases. Of great concern are carbapenem resistant <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa,</i> and <i>Acinetobacter baumannii</i>. Despite the need for rapid AMR diagnostics globally, current molecular detection methods often require expensive equipment and trained personnel. Here, we present a novel machine-learning-aided platform for the rapid detection of ESBLs and carbapenemases using Loop-mediated isothermal Amplification (LAMP). The platform consists of (i) an affordable device for sample lysis, LAMP amplification, and visual fluorometric detection; (ii) a LAMP screening panel to detect the most common ESBL and carbapenemase genes; and (iii) a smartphone application for automated interpretation of results. Validation studies on clinical isolates and urine samples demonstrated percent positive and negative agreements above 95% for all targets. Accuracy, precision, and recall values of the machine learning model deployed in the smartphone application were all above 92%. Providing a simplified workflow, minimal operation training, and results in less than an hour, this study demonstrated the platform's feasibility for near-patient testing in resource-limited settings.IMPORTANCEExtended-spectrum beta-lactamases (ESBL) and carbapenemases confer resistance to third-generation cephalosporins and carbapenems in pathogenic Gram-negative bacteria such as <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa,</i> and <i>Acinetobacter baumannii</i>. Conventional antimicrobial susceptibility testing is based on phenotypic methods, and results can take several days to be obtained. Current genotypic detection methods can be rapid but require expensive equipment and trained personnel. In this study, we present a novel machine learning-aided platform for the rapid detection of ESBLs and carbapenemases using Loop-mediated isothermal Amplification (LAMP). The validation of the platform demonstrated percent positive and negative agreements above 95% for all targets. The newly developed platform provided a simplified workflow, minimal technical training, and results in less than an hour. This study demonstrated the platform's feasibility for rapid testing of ESBL and carbapenemases in bacteria and urine specimens.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shedding of nontyphoidal Salmonella by asymptomatic convalescing children under 5 years as a risk factor for invasive disease in Mukuru informal settlement in Nairobi, Kenya. 肯尼亚内罗毕 Mukuru 非正规居住区 5 岁以下无症状康复儿童的非伤寒沙门氏菌散播是侵袭性疾病的风险因素。
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-24 DOI: 10.1128/jcm.00750-24
Kelvin Kering, Kariuki Njaanake, Celestine Wairimu, Marianne Mureithi, Collins Kebenei, Georgina Odityo, Michael Mugo, Susan M Kavai, Cecilia Mbae, Kristin Weber, Michael Pietsch, Tanja Pilz, Oliver Drechsel, Andrea Thürmer, Torsten Semmler, Stephan Fuchs, Sandra Simon, Antje Flieger, Lothar H Wieler, Samuel Kariuki

Nontyphoidal Salmonella (NTS) is a predominant cause of invasive disease in sub-Saharan Africa especially among children under 5 years. Asymptomatic fecal shedding of NTS is hypothesized to contribute to the human-to-human transmission of NTS especially in low-resource settings. However, the role of pathogen shedding in invasive disease is unknown. This study aimed to investigate the prevalence and duration of fecal shedding of NTS among children under 5 years convalescing from invasive NTS disease and among healthy individuals in the community. Children presenting with fever of ≥38°C with or without diarrhea were recruited at four health facilities in Nairobi, between June 2021 and August 2023. Blood and stool samples collected were subjected to culture for the isolation of NTS (S. Enteritidis and S. Typhimurium). Children with NTS culture-positive samples (index cases) were followed up post-acute disease where household contacts and controls provided stool samples for isolation of NTS. NTS prevalence among the 3,293 individuals recruited was 1.52%. Asymptomatic shedding post-treatment was observed in almost one-third (31%) of the 42 index cases followed up. Of the 13 with intestinal shedding, 7 were shedding NTS of the same sequence type (ST) as the one recovered during acute disease. The longest duration of intestinal shedding was 3 months post-treatment. Of the 241 healthy individuals recruited, 8 had asymptomatic shedding of NTS, and 2 of these were closely related to those recovered from index cases. These findings support the hypothesis of human-to-human transmission of NTS in sub-Saharan Africa highlighting the possible benefit of vaccine introduction.

Importance: Asymptomatic fecal shedding of nontyphoidal Salmonella (NTS) is hypothesized to contribute to the human-to-human transmission of NTS especially in low-resource settings which could lead to invasive disease among high-risk populations, especially children. Our findings reiterate the hypothesis that human reservoirs could be important in the transmission of nontyphoidal Salmonella in sub-Saharan Africa. This underscores the importance of developing infection prevention measures which could include vaccine deployment and improving water, sanitation and hygiene infrastructure.

非伤寒沙门氏菌(NTS)是撒哈拉以南非洲地区侵袭性疾病的主要病因,尤其是在 5 岁以下儿童中。据推测,NTS的无症状粪便脱落会导致NTS的人际传播,尤其是在资源匮乏的环境中。然而,病原体脱落在侵袭性疾病中的作用尚不清楚。本研究旨在调查侵袭性 NTS 疾病康复期 5 岁以下儿童和社区健康人群中 NTS 粪便脱落的流行率和持续时间。2021 年 6 月至 2023 年 8 月期间,在内罗毕的四家医疗机构招募了发烧≥38°C 并伴有或不伴有腹泻的儿童。采集的血液和粪便样本经培养后分离出 NTS(肠道病毒和鼠伤寒杆菌)。对 NTS 培养呈阳性的儿童(指数病例)进行急性病后随访,由家庭接触者和对照组提供粪便样本以分离 NTS。在招募的 3293 人中,NTS 感染率为 1.52%。在随访的 42 例病例中,有近三分之一(31%)在治疗后出现无症状脱落。在 13 例出现肠道脱落的病例中,有 7 例脱落的 NTS 与急性期恢复的 NTS 序列类型 (ST) 相同。肠道脱落最长持续时间为治疗后 3 个月。在招募的 241 名健康人中,有 8 人的 NTS 无症状脱落,其中 2 人的 NTS 与指数病例中的 NTS 密切相关。这些发现支持了撒哈拉以南非洲地区 NTS 人际传播的假设,强调了引入疫苗可能带来的益处:据推测,无症状粪便脱落的非伤寒沙门氏菌(NTS)会导致NTS的人际传播,尤其是在资源匮乏的环境中,这可能会导致高危人群(尤其是儿童)患上侵袭性疾病。我们的研究结果重申了这一假设,即人类储库可能是撒哈拉以南非洲非伤寒沙门氏菌传播的重要因素。这强调了制定感染预防措施的重要性,这些措施可包括部署疫苗和改善水、环境卫生和个人卫生基础设施。
{"title":"Shedding of nontyphoidal <i>Salmonella</i> by asymptomatic convalescing children under 5 years as a risk factor for invasive disease in Mukuru informal settlement in Nairobi, Kenya.","authors":"Kelvin Kering, Kariuki Njaanake, Celestine Wairimu, Marianne Mureithi, Collins Kebenei, Georgina Odityo, Michael Mugo, Susan M Kavai, Cecilia Mbae, Kristin Weber, Michael Pietsch, Tanja Pilz, Oliver Drechsel, Andrea Thürmer, Torsten Semmler, Stephan Fuchs, Sandra Simon, Antje Flieger, Lothar H Wieler, Samuel Kariuki","doi":"10.1128/jcm.00750-24","DOIUrl":"https://doi.org/10.1128/jcm.00750-24","url":null,"abstract":"<p><p>Nontyphoidal <i>Salmonella</i> (NTS) is a predominant cause of invasive disease in sub-Saharan Africa especially among children under 5 years. Asymptomatic fecal shedding of NTS is hypothesized to contribute to the human-to-human transmission of NTS especially in low-resource settings. However, the role of pathogen shedding in invasive disease is unknown. This study aimed to investigate the prevalence and duration of fecal shedding of NTS among children under 5 years convalescing from invasive NTS disease and among healthy individuals in the community. Children presenting with fever of ≥38°C with or without diarrhea were recruited at four health facilities in Nairobi, between June 2021 and August 2023. Blood and stool samples collected were subjected to culture for the isolation of NTS (<i>S</i>. Enteritidis and <i>S</i>. Typhimurium). Children with NTS culture-positive samples (index cases) were followed up post-acute disease where household contacts and controls provided stool samples for isolation of NTS. NTS prevalence among the 3,293 individuals recruited was 1.52%. Asymptomatic shedding post-treatment was observed in almost one-third (31%) of the 42 index cases followed up. Of the 13 with intestinal shedding, 7 were shedding NTS of the same sequence type (ST) as the one recovered during acute disease. The longest duration of intestinal shedding was 3 months post-treatment. Of the 241 healthy individuals recruited, 8 had asymptomatic shedding of NTS, and 2 of these were closely related to those recovered from index cases. These findings support the hypothesis of human-to-human transmission of NTS in sub-Saharan Africa highlighting the possible benefit of vaccine introduction.</p><p><strong>Importance: </strong>Asymptomatic fecal shedding of nontyphoidal <i>Salmonella</i> (NTS) is hypothesized to contribute to the human-to-human transmission of NTS especially in low-resource settings which could lead to invasive disease among high-risk populations, especially children. Our findings reiterate the hypothesis that human reservoirs could be important in the transmission of nontyphoidal <i>Salmonella</i> in sub-Saharan Africa. This underscores the importance of developing infection prevention measures which could include vaccine deployment and improving water, sanitation and hygiene infrastructure.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Candida guilliermondii fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center. Guilliermondii 念珠菌菌血症:参考实验室和三级医疗中心抗菌药敏感性模式的 12 年回顾性研究。
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-23 DOI: 10.1128/jcm.01057-24
Jack W McHugh, David R Bayless, Nischal Ranganath, Ryan W Stevens, Dalton R Kind, Nancy L Wengenack, Aditya S Shah

The prevalence of invasive candidiasis caused by non-albicans Candida species is increasing. Candida guilliermondii is an infrequent cause of candidemia but has been associated with decreased susceptibility to triazoles. Clinical data related to the infection with C. guilliermondii are sparse. Our study evaluated the antifungal susceptibility testing (AST) for C. guilliermondii isolates submitted to a reference laboratory over a 12-year period (2012-2023). AST patterns were examined using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cutoff values (ECVs) and breakpoints. Where isolates were identified from patients treated at our institution, retrospective chart review was performed to describe patient risk factors, treatment approaches, and outcomes associated with C. guilliermondii fungemia. One hundred twelve blood culture isolates of C. guilliermondii were identified, and clinical data were available for 21 fungemic patients. A significant number of isolates (9.8-20.5%) were observed to be non-wild type for various triazoles. All isolates were susceptible to micafungin. A majority (76.2%) of cases of C. guilliermondii fungemia treated at our tertiary care center were hospital-acquired, and two-thirds of patients were immunocompromised at the time of diagnosis. Ten of the 21 patients died within 60 days of fungemia, although mortality was directly or partially attributed to C. guilliermondii fungemia in only four cases (19.0%). Echinocandins may be used for empiric therapy for C. guilliermondii until the results of AST are available. Further research is required to determine appropriate clinical breakpoints for triazoles.

Importance: Our study addresses a significant knowledge gap in the clinical management of this non-Candida albicans species. Our retrospective review includes comprehensive AST data for 112 Candida guilliermondii isolates, which is the largest number of isolates reported from the United States to date. Susceptibility data are supplemented by clinical outcomes, where isolates were identified for patients treated at Mayo Clinic. Key findings from our study include the observation that a notable proportion of C. guilliermondii isolates exhibit non-wild-type profiles for various triazoles. Importantly, all isolates remained susceptible to echinocandins, suggesting their efficacy as first-line therapy in the absence of timely susceptibility results. Furthermore, our study highlights the high mortality associated with C. guilliermondii fungemia in immunocompromised patients, emphasizing the urgent need for optimized treatment strategies.

由非阿氏念珠菌引起的侵袭性念珠菌病的发病率正在上升。guilliermondii 念珠菌是念珠菌血症的一个不常见原因,但与对三唑类药物的敏感性降低有关。与guilliermondii念珠菌感染有关的临床数据很少。我们的研究评估了 12 年内(2012-2023 年)提交给参考实验室的 C. guilliermondii 分离物的抗真菌药敏试验 (AST)。采用临床与实验室标准协会(CLSI)和欧洲抗菌药物敏感性检测委员会(EUCAST)的流行病学截断值(ECV)和断点对 AST 模式进行了检测。在本机构接受治疗的患者中发现分离物时,我们进行了回顾性病历审查,以描述与吉氏真菌血症相关的患者风险因素、治疗方法和结果。共鉴定出 112 株血液培养分离出的吉氏真菌,并获得了 21 例真菌血症患者的临床数据。观察到大量分离株(9.8%-20.5%)对各种三唑类药物均为非野生型。所有分离株都对米卡芬净敏感。在我们的三级医疗中心治疗的大多数(76.2%)吉氏真菌血症病例都是在医院获得的,三分之二的患者在确诊时免疫力低下。21例患者中有10例在真菌血症发生后60天内死亡,但只有4例(19.0%)患者的死亡直接或部分归因于吉氏真菌血症。在获得 AST 结果之前,棘白菌素可用于治疗吉氏真菌的经验疗法。需要进一步研究确定三唑类药物的适当临床断点:重要意义:我们的研究填补了非白色念珠菌临床治疗方面的一个重大知识空白。我们的回顾性研究包括 112 株 Guilliermondii 念珠菌分离株的全面 AST 数据,这是迄今为止从美国报告的最大数量的分离株。在梅奥诊所接受治疗的患者的分离物中发现的临床结果补充了易感性数据。我们研究的主要发现包括观察到相当一部分吉列蒙第孢子菌分离株对各种三唑类药物表现出非野生型特征。重要的是,所有分离株对棘白菌素仍然敏感,这表明在没有及时获得药敏结果的情况下,棘白菌素可作为一线治疗药物。此外,我们的研究还突显了免疫力低下的患者中与吉氏真菌病相关的高死亡率,强调了优化治疗策略的迫切需要。
{"title":"<i>Candida guilliermondii</i> fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center.","authors":"Jack W McHugh, David R Bayless, Nischal Ranganath, Ryan W Stevens, Dalton R Kind, Nancy L Wengenack, Aditya S Shah","doi":"10.1128/jcm.01057-24","DOIUrl":"https://doi.org/10.1128/jcm.01057-24","url":null,"abstract":"<p><p>The prevalence of invasive candidiasis caused by non-<i>albicans Candida</i> species is increasing. <i>Candida guilliermondii</i> is an infrequent cause of candidemia but has been associated with decreased susceptibility to triazoles. Clinical data related to the infection with <i>C. guilliermondii</i> are sparse. Our study evaluated the antifungal susceptibility testing (AST) for <i>C. guilliermondii</i> isolates submitted to a reference laboratory over a 12-year period (2012-2023). AST patterns were examined using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cutoff values (ECVs) and breakpoints. Where isolates were identified from patients treated at our institution, retrospective chart review was performed to describe patient risk factors, treatment approaches, and outcomes associated with <i>C. guilliermondii</i> fungemia. One hundred twelve blood culture isolates of <i>C. guilliermondii</i> were identified, and clinical data were available for 21 fungemic patients. A significant number of isolates (9.8-20.5%) were observed to be non-wild type for various triazoles. All isolates were susceptible to micafungin. A majority (76.2%) of cases of <i>C. guilliermondii</i> fungemia treated at our tertiary care center were hospital-acquired, and two-thirds of patients were immunocompromised at the time of diagnosis. Ten of the 21 patients died within 60 days of fungemia, although mortality was directly or partially attributed to <i>C. guilliermondii</i> fungemia in only four cases (19.0%). Echinocandins may be used for empiric therapy for <i>C. guilliermondii</i> until the results of AST are available. Further research is required to determine appropriate clinical breakpoints for triazoles.</p><p><strong>Importance: </strong>Our study addresses a significant knowledge gap in the clinical management of this non-<i>Candida albicans</i> species. Our retrospective review includes comprehensive AST data for 112 <i>Candida guilliermondii</i> isolates, which is the largest number of isolates reported from the United States to date. Susceptibility data are supplemented by clinical outcomes, where isolates were identified for patients treated at Mayo Clinic. Key findings from our study include the observation that a notable proportion of <i>C. guilliermondii</i> isolates exhibit non-wild-type profiles for various triazoles. Importantly, all isolates remained susceptible to echinocandins, suggesting their efficacy as first-line therapy in the absence of timely susceptibility results. Furthermore, our study highlights the high mortality associated with <i>C. guilliermondii</i> fungemia in immunocompromised patients, emphasizing the urgent need for optimized treatment strategies.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical pilot of bacterial transcriptional profiling as a combined genotypic and phenotypic antimicrobial susceptibility test. 细菌转录谱分析作为基因型和表型抗菌药敏感性联合检测的临床试验。
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-21 DOI: 10.1128/jcm.00997-24
E L Young, D J Roach, M A Martinsen, G E G McGrath, N R Holbrook, H E Cho, E Y Seyoum, V M Pierce, R P Bhattacharyya

Antimicrobial resistance is a growing health threat, but standard methods for determining antibiotic susceptibility are slow and can delay optimal treatment, which is especially consequential in severe infections such as bacteremia. Novel approaches for rapid susceptibility profiling have emerged that characterize either bacterial response to antibiotics (phenotype) or detect specific resistance genes (genotype). Genotypic and Phenotypic AST through RNA detection (GoPhAST-R) is a novel assay, performed directly on positive blood cultures, that integrates rapid transcriptional response profiling with the detection of key resistance gene transcripts, thereby providing simultaneous data on both phenotype and genotype. Here, we performed the first clinical pilot of GoPhAST-R on 42 positive blood cultures: 26 growing Escherichia coli, 15 growing Klebsiella pneumoniae, and 1 with both. An aliquot of each positive blood culture was exposed to nine different antibiotics, lysed, and underwent rapid transcriptional profiling on the NanoString platform; results were analyzed using an in-house susceptibility classification algorithm. GoPhAST-R achieved 95% overall agreement with standard antimicrobial susceptibility testing methods, with the highest agreement for beta-lactams (98%) and the lowest for fluoroquinolones (88%). Epidemic resistance genes including the extended spectrum beta-lactamase blaCTX-M-15 and the carbapenemase blaKPC were also detected within the population. This study demonstrates the clinical feasibility of using transcriptional response profiling for rapid resistance determination, although further validation with larger and more diverse bacterial populations will be essential in future work. GoPhAST-R represents a promising new approach for rapid and comprehensive antibiotic susceptibility testing in clinical settings.IMPORTANCEExposure to antibiotics causes differential transcriptional signatures in susceptible vs resistant bacteria. These differences can be leveraged to rapidly predict resistance profiles of Escherichia coli and Klebsiella pneumoniae in clinically positive blood cultures.

抗生素耐药性对健康的威胁与日俱增,但确定抗生素敏感性的标准方法进展缓慢,可能会延误最佳治疗时间,尤其是在菌血症等严重感染中。新出现的快速易感性分析方法可以描述细菌对抗生素的反应(表型)或检测特定的耐药基因(基因型)。通过 RNA 检测基因型和表型 AST(GoPhAST-R)是一种直接在阳性血液培养物上进行的新型检测方法,它将快速转录反应谱分析与关键耐药基因转录本检测结合在一起,从而同时提供表型和基因型数据。在此,我们对 42 份阳性血液培养物进行了 GoPhAST-R 的首次临床试验:其中 26 份培养出大肠埃希菌,15 份培养出肺炎克雷伯菌,1 份同时培养出两种细菌。每个阳性血培养物的等分试样都暴露于 9 种不同的抗生素,裂解后在 NanoString 平台上进行快速转录剖析;使用内部药敏性分类算法对结果进行分析。GoPhAST-R 与标准抗菌素药敏测试方法的总体一致性达到 95%,其中β-内酰胺类药物的一致性最高(98%),氟喹诺酮类药物的一致性最低(88%)。在人群中还检测到了流行性耐药基因,包括广谱β-内酰胺酶blaCTX-M-15和碳青霉烯酶blaKPC。这项研究证明了利用转录反应图谱进行快速耐药性测定的临床可行性,不过在今后的工作中还必须利用更大、更多样化的细菌群体进行进一步验证。GoPhAST-R 是在临床环境中进行快速、全面抗生素敏感性测试的一种很有前途的新方法。重要意义暴露于抗生素会导致易感细菌和耐药细菌的转录特征出现差异。利用这些差异可以快速预测临床阳性血液培养物中大肠埃希菌和肺炎克雷伯菌的耐药性特征。
{"title":"Clinical pilot of bacterial transcriptional profiling as a combined genotypic and phenotypic antimicrobial susceptibility test.","authors":"E L Young, D J Roach, M A Martinsen, G E G McGrath, N R Holbrook, H E Cho, E Y Seyoum, V M Pierce, R P Bhattacharyya","doi":"10.1128/jcm.00997-24","DOIUrl":"10.1128/jcm.00997-24","url":null,"abstract":"<p><p>Antimicrobial resistance is a growing health threat, but standard methods for determining antibiotic susceptibility are slow and can delay optimal treatment, which is especially consequential in severe infections such as bacteremia. Novel approaches for rapid susceptibility profiling have emerged that characterize either bacterial response to antibiotics (phenotype) or detect specific resistance genes (genotype). <u>G</u>en<u>o</u>typic and <u>Ph</u>enotypic <u>AST</u> through <u>R</u>NA detection (GoPhAST-R) is a novel assay, performed directly on positive blood cultures, that integrates rapid transcriptional response profiling with the detection of key resistance gene transcripts, thereby providing simultaneous data on both phenotype and genotype. Here, we performed the first clinical pilot of GoPhAST-R on 42 positive blood cultures: 26 growing <i>Escherichia coli</i>, 15 growing <i>Klebsiella pneumoniae</i>, and 1 with both. An aliquot of each positive blood culture was exposed to nine different antibiotics, lysed, and underwent rapid transcriptional profiling on the NanoString platform; results were analyzed using an in-house susceptibility classification algorithm. GoPhAST-R achieved 95% overall agreement with standard antimicrobial susceptibility testing methods, with the highest agreement for beta-lactams (98%) and the lowest for fluoroquinolones (88%). Epidemic resistance genes including the extended spectrum beta-lactamase <i>bla</i><sub>CTX-M-15</sub> and the carbapenemase <i>bla</i><sub>KPC</sub> were also detected within the population. This study demonstrates the clinical feasibility of using transcriptional response profiling for rapid resistance determination, although further validation with larger and more diverse bacterial populations will be essential in future work. GoPhAST-R represents a promising new approach for rapid and comprehensive antibiotic susceptibility testing in clinical settings.IMPORTANCEExposure to antibiotics causes differential transcriptional signatures in susceptible vs resistant bacteria. These differences can be leveraged to rapidly predict resistance profiles of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in clinically positive blood cultures.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Approaches to developing and implementing a molecular diagnostics stewardship program for infectious diseases: an ASM Laboratory Practices Subcommittee report. 制定和实施传染病分子诊断监管计划的方法:ASM 实验室规范小组委员会报告。
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-21 DOI: 10.1128/jcm.00941-24
Frances Valencia-Shelton, Neil Anderson, Elizabeth L Palavecino, Maria E Navas, Paige M K Larkin, Rosemary She, Laura M Filkins

Diagnostic stewardship (DxS) for infectious disease testing requires a multi-disciplinary approach to optimize test selection, performance, interpretation and patient treatment. Nucleic acid amplification-based tests for the diagnosis of infectious diseases, or "molecular microbiology tests," have rapidly expanded over the past two decades. With the increased availability and complexity of these tests, there is also an increased need for collaborative approaches to optimize test use to promote positive impacts on patient care, while mitigating potential negative impact or resource waste. In this review, we provide recommendations on building collaborative DxS teams, including microbiologists and the diverse stakeholders that use and interpret molecular microbiology tests. We then detail approaches to identify high-priority molecular microbiology tests that may need utilization assessment, select appropriate diagnostic stewardship interventions, and monitor the impact of implemented interventions. This strategic process may be employed by laboratories to realize optimal testing for selected tests at their institution.

传染病检测的诊断管理(DxS)要求采用多学科方法来优化检测的选择、性能、解释和患者治疗。过去二十年来,基于核酸扩增的传染病诊断检测(或称 "分子微生物学检测")迅速发展。随着这些检验的可用性和复杂性的增加,人们也越来越需要通过合作的方式来优化检验的使用,以促进对患者护理的积极影响,同时减少潜在的负面影响或资源浪费。在本综述中,我们就建立 DxS 协作团队(包括微生物学家以及使用和解释分子微生物学检验的不同利益相关者)提出了建议。然后,我们详细介绍了确定可能需要进行利用率评估的高优先级分子微生物学检验、选择适当的诊断监管干预措施以及监控已实施干预措施的影响的方法。实验室可采用这一战略流程,以实现对其机构所选检验项目的最佳检验。
{"title":"Approaches to developing and implementing a molecular diagnostics stewardship program for infectious diseases: an ASM Laboratory Practices Subcommittee report.","authors":"Frances Valencia-Shelton, Neil Anderson, Elizabeth L Palavecino, Maria E Navas, Paige M K Larkin, Rosemary She, Laura M Filkins","doi":"10.1128/jcm.00941-24","DOIUrl":"https://doi.org/10.1128/jcm.00941-24","url":null,"abstract":"<p><p>Diagnostic stewardship (DxS) for infectious disease testing requires a multi-disciplinary approach to optimize test selection, performance, interpretation and patient treatment. Nucleic acid amplification-based tests for the diagnosis of infectious diseases, or \"molecular microbiology tests,\" have rapidly expanded over the past two decades. With the increased availability and complexity of these tests, there is also an increased need for collaborative approaches to optimize test use to promote positive impacts on patient care, while mitigating potential negative impact or resource waste. In this review, we provide recommendations on building collaborative DxS teams, including microbiologists and the diverse stakeholders that use and interpret molecular microbiology tests. We then detail approaches to identify high-priority molecular microbiology tests that may need utilization assessment, select appropriate diagnostic stewardship interventions, and monitor the impact of implemented interventions. This strategic process may be employed by laboratories to realize optimal testing for selected tests at their institution.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GPT-4-based AI agents-the new expert system for detection of antimicrobial resistance mechanisms? 基于 GPT-4 的人工智能代理--检测抗菌素耐药性机制的新专家系统?
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-17 DOI: 10.1128/jcm.00689-24
Christian G Giske, Michelle Bressan, Farah Fiechter, Vladimira Hinic, Stefano Mancini, Oliver Nolte, Adrian Egli
<p><p>The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends two steps for detecting beta-lactamases in Gram-negative bacteria. Screening for potential extended-spectrum beta-lactamase (ESBL), plasmid-mediated AmpC beta-lactamase, or carbapenemase production is confirmed. We aimed to validate generative pre-trained transformer (GPT)-4 and GPT-agent for pre-classification of disk diffusion to indicate potential beta-lactamases. We assigned 225 Gram-negative isolates based on phenotypic resistances against beta-lactam antibiotics and additional tests to one or more resistance mechanisms as follows: "none," "ESBL," "AmpC," or "carbapenemase." Next, we customized a GPT-agent with EUCAST guidelines and breakpoint table (v13.1). We compared routine diagnostics (reference) to those of (i) EUCAST-GPT-expert, (ii) microbiologists, and (iii) non-customized GPT-4. We determined sensitivities and specificities to flag suspect resistances. Three microbiologists showed concordance in 814/862 (94.4%) phenotypic categories and were used in median eight words (interquartile range [IQR] 4-11) for reasoning. Median sensitivity/specificity for ESBL, AmpC, and carbapenemase were 98%/99.1%, 96.8%/97.1%, and 95.5%/98.5%, respectively. Three prompts of EUCAST-GPT-expert showed concordance in 706/862 (81.9%) categories but were used in median 158 words (IQR 140-174) for reasoning. Sensitivity/specificity for ESBL, AmpC, and carbapenemase prediction were 95.4%/69.23%, 96.9%/86.3%, and 100%/98.8%, respectively. Non-customized GPT-4 could interpret 169/862 (19.6%) categories, and 137/169 (81.1%) agreed with routine diagnostics. Non-customized GPT-4 was used in median 85 words (IQR 72-105) for reasoning. Microbiologists showed higher concordance and shorter argumentations compared to GPT-agents. Humans showed higher specificities compared to GPT-agents. GPT-agent's unspecific flagging of ESBL and AmpC potentially results in additional testing, diagnostic delays, and higher costs. GPT-4 is not approved by regulatory bodies, but validation of large language models is needed.</p><p><strong>Importance: </strong>The study titled "GPT-4-based AI agents-the new expert system for detection of antimicrobial resistance mechanisms?" is critically important as it explores the integration of advanced artificial intelligence (AI) technologies, like generative pre-trained transformer (GPT)-4, into the field of laboratory medicine, specifically in the diagnostics of antimicrobial resistance (AMR). With the growing challenge of AMR, there is a pressing need for innovative solutions that can enhance diagnostic accuracy and efficiency. This research assesses the capability of AI to support the existing two-step confirmatory process recommended by the European Committee on Antimicrobial Susceptibility Testing for detecting beta-lactamases in Gram-negative bacteria. By potentially speeding up and improving the precision of initial screenings, AI could reduce the time
欧洲抗菌药物敏感性检测委员会(EUCAST)建议采用两个步骤检测革兰氏阴性细菌中的β-内酰胺酶。对潜在的广谱β-内酰胺酶(ESBL)、质粒介导的 AmpC β-内酰胺酶或碳青霉烯酶的产生进行筛选确认。我们的目的是验证生成式预训练转换器(GPT)-4 和 GPT-agent,通过对磁盘扩散进行预分类来指示潜在的β-内酰胺酶。根据对β-内酰胺类抗生素的表型耐药性和其他测试结果,我们将 225 个革兰氏阴性分离株归入一种或多种耐药机制,具体如下:无"、"ESBL"、"AmpC "或 "碳青霉烯酶"。接下来,我们根据 EUCAST 指南和断点表(v13.1)定制了 GPT 试剂。我们将常规诊断(参考)与 (i) EUCAST GPT 专家、(ii) 微生物学家和 (iii) 非定制 GPT-4 的诊断进行了比较。我们确定了标记可疑耐药性的敏感性和特异性。三位微生物学家在 814/862 个(94.4%)表型类别中显示出一致性,并以中位数 8 个字(四分位数间距 [IQR] 4-11)进行推理。ESBL、AmpC和碳青霉烯酶的敏感性/特异性中位数分别为98%/99.1%、96.8%/97.1%和95.5%/98.5%。EUCAST-GPT-expert 的三个提示在 706/862 个(81.9%)类别中显示出一致性,但推理所用字数中位数为 158 个(IQR 140-174)。ESBL、AmpC和碳青霉烯酶预测的灵敏度/特异性分别为95.4%/69.23%、96.9%/86.3%和100%/98.8%。非定制 GPT-4 可解释 169/862(19.6%)个类别,137/169(81.1%)个类别与常规诊断一致。非定制 GPT-4 的推理用词中位数为 85 个(IQR 72-105)。与 GPT 代理相比,微生物学家显示出更高的一致性和更短的论证时间。与 GPT 代理相比,人类表现出更高的特异性。GPT-agent 对 ESBL 和 AmpC 的非特异性标记可能会导致额外的检测、诊断延迟和更高的成本。监管机构尚未批准 GPT-4,但需要对大型语言模型进行验证:这项题为 "基于 GPT-4 的人工智能代理--检测抗菌素耐药性机制的新专家系统?"的研究具有极其重要的意义,因为它探讨了将生成式预训练转换器(GPT)-4 等先进的人工智能(AI)技术融入实验室医学领域,特别是抗菌素耐药性(AMR)诊断领域的问题。随着 AMR 的挑战日益严峻,人们迫切需要能够提高诊断准确性和效率的创新解决方案。这项研究评估了人工智能支持欧洲抗菌药敏感性测试委员会推荐的现有两步确证流程的能力,以检测革兰氏阴性细菌中的β-内酰胺酶。人工智能有可能加快并提高初步筛查的精确度,从而缩短采取适当治疗干预措施的时间。此外,这项研究对于验证人工智能工具在临床环境中的可靠性和安全性至关重要,它能确保人工智能工具在广泛应用之前符合严格的监管标准。这可能预示着实验室诊断方式的重大转变,最终为患者带来更好的治疗效果。
{"title":"GPT-4-based AI agents-the new expert system for detection of antimicrobial resistance mechanisms?","authors":"Christian G Giske, Michelle Bressan, Farah Fiechter, Vladimira Hinic, Stefano Mancini, Oliver Nolte, Adrian Egli","doi":"10.1128/jcm.00689-24","DOIUrl":"https://doi.org/10.1128/jcm.00689-24","url":null,"abstract":"&lt;p&gt;&lt;p&gt;The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends two steps for detecting beta-lactamases in Gram-negative bacteria. Screening for potential extended-spectrum beta-lactamase (ESBL), plasmid-mediated AmpC beta-lactamase, or carbapenemase production is confirmed. We aimed to validate generative pre-trained transformer (GPT)-4 and GPT-agent for pre-classification of disk diffusion to indicate potential beta-lactamases. We assigned 225 Gram-negative isolates based on phenotypic resistances against beta-lactam antibiotics and additional tests to one or more resistance mechanisms as follows: \"none,\" \"ESBL,\" \"AmpC,\" or \"carbapenemase.\" Next, we customized a GPT-agent with EUCAST guidelines and breakpoint table (v13.1). We compared routine diagnostics (reference) to those of (i) EUCAST-GPT-expert, (ii) microbiologists, and (iii) non-customized GPT-4. We determined sensitivities and specificities to flag suspect resistances. Three microbiologists showed concordance in 814/862 (94.4%) phenotypic categories and were used in median eight words (interquartile range [IQR] 4-11) for reasoning. Median sensitivity/specificity for ESBL, AmpC, and carbapenemase were 98%/99.1%, 96.8%/97.1%, and 95.5%/98.5%, respectively. Three prompts of EUCAST-GPT-expert showed concordance in 706/862 (81.9%) categories but were used in median 158 words (IQR 140-174) for reasoning. Sensitivity/specificity for ESBL, AmpC, and carbapenemase prediction were 95.4%/69.23%, 96.9%/86.3%, and 100%/98.8%, respectively. Non-customized GPT-4 could interpret 169/862 (19.6%) categories, and 137/169 (81.1%) agreed with routine diagnostics. Non-customized GPT-4 was used in median 85 words (IQR 72-105) for reasoning. Microbiologists showed higher concordance and shorter argumentations compared to GPT-agents. Humans showed higher specificities compared to GPT-agents. GPT-agent's unspecific flagging of ESBL and AmpC potentially results in additional testing, diagnostic delays, and higher costs. GPT-4 is not approved by regulatory bodies, but validation of large language models is needed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;The study titled \"GPT-4-based AI agents-the new expert system for detection of antimicrobial resistance mechanisms?\" is critically important as it explores the integration of advanced artificial intelligence (AI) technologies, like generative pre-trained transformer (GPT)-4, into the field of laboratory medicine, specifically in the diagnostics of antimicrobial resistance (AMR). With the growing challenge of AMR, there is a pressing need for innovative solutions that can enhance diagnostic accuracy and efficiency. This research assesses the capability of AI to support the existing two-step confirmatory process recommended by the European Committee on Antimicrobial Susceptibility Testing for detecting beta-lactamases in Gram-negative bacteria. By potentially speeding up and improving the precision of initial screenings, AI could reduce the time ","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Photo Quiz: Eccentric target sign in renal transplant recipient. 照片测验:肾移植受者的偏心靶征。
IF 6.1 2区 医学 Q1 MICROBIOLOGY Pub Date : 2024-10-16 DOI: 10.1128/jcm.00298-24
Mahdi Ouafi, Caroline Couvreur, Arnaud Salmon-Rousseau, Anne-Sophie Deleplancque, Sarah Stabler, Claude-Alain Maurage, Camille Cordier
{"title":"Photo Quiz: Eccentric target sign in renal transplant recipient.","authors":"Mahdi Ouafi, Caroline Couvreur, Arnaud Salmon-Rousseau, Anne-Sophie Deleplancque, Sarah Stabler, Claude-Alain Maurage, Camille Cordier","doi":"10.1128/jcm.00298-24","DOIUrl":"10.1128/jcm.00298-24","url":null,"abstract":"","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11481496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Microbiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1